• Explore /
  • Poster
  • / SAPPHIRE: A randomized phase II study of mFOLFOX6 + panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6 + panitumumab in patients with colorectal cancer.

SAPPHIRE: A randomized phase II study of mFOLFOX6 + panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6 + panitumumab in patients with colorectal cancer.

Abstract Poster

Authors

null

Masato Nakamura

Aizawa Hospital, Matsumoto, Japan

Masato Nakamura , Yoshinori Munemoto , Masazumi Takahashi , Masahito Kotaka , Hiroaki Kuroda , Takeshi Kato , Noritaka Minagawa , Shingo Noura , Mutsumi Fukunaga , Hidekazu Kuramochi , Tetsuo Touyama , Takao Takahashi , Yoshito Akagi , Hironaga Satake , Shuichi Kurosawa , Tomoko Miura , Hideyuki Mishima , Junichi Sakamoto , Koji Oba , Naoki Nagata

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02337946

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 729)

DOI

10.1200/JCO.2018.36.4_suppl.729

Abstract #

729

Poster Bd #

H18

Abstract Disclosures

Similar Posters

First Author: Dominik Paul Modest

First Author: David Malka

First Author: Mitsukuni Suenaga

Poster

2014 Gastrointestinal Cancers Symposium

Cost differential among systemic therapies for colon cancer.

Cost differential among systemic therapies for colon cancer.

First Author: Hasan Nadeem